| Overview |
| bs-3636R-PE |
| MO25 alpha/CAB39 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat, Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MO25 alpha/CAB39 |
| 201-300/341 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 51719 |
| Cytoplasm |
| CAB39; Calcium binding protein 39; CGI 66; CGI66; MO25 alpha; MO25; Mouse protein 25 alpha; Protein Mo25. |
| Mouse protein 25 alpha (MO25 alpha, CAB39) is a 40-kDa protein that, together with the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase, forms a regulatory complex capable of stimulating the activity of the LKB1 tumor suppressor protein kinase. The latter is mutated in the inherited Peutz-Jeghers cancer syndrome (PJS). CAB39 binds directly to a conserved Trp-Glu-Phe sequence at the STRAD alpha C terminus, markedly enhancing binding of STRAD alpha to LKB1 and increasing LKB1 catalytic activity. Skeletal muscle contraction results in the phosphorylation and activation of the AMP-activated protein kinase (AMPK) by an upstream kinase (AMPKK). The LKB1-STE-related adaptor (STRAD)-mouse protein 25 (MO25) complex is the major AMPKK in skeletal muscle; however, LKB1-STRAD-MO25 activity is not increased by muscle contraction. This relationship suggests that phosphorylation of AMPK by LKB1-STRAD-MO25 during skeletal muscle contraction may be regulated by allosteric mechanisms. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz